Know Cancer

forgot password

A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere® (Docetaxel) in the Treatment of Subjects With Solid Tumors

Phase 1
18 Years
Not Enrolling
Solid Tumor

Thank you

Trial Information

A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere® (Docetaxel) in the Treatment of Subjects With Solid Tumors

Inclusion Criteria

Inclusion Criteria

- Subject must be greater then or equal to 18 years of age.

- Subject must have a histologically and/or cytologically documented cancer for which
docetaxel has been determined to be an appropriate therapy, per the Investigator.

- Subject must have evaluable and/or measurable disease by Computed Tomography (CT) or
Magnetic Resonance Imaging (MRI) as defined by RECIST.

- Subjects with brain metastases must have clinically controlled neurologic symptoms,
defined as surgical excision and/or radiation therapy followed by 21 days of stable
neurologic function and no evidence of CNS disease progression as determined by CT or
MRI within 28 days prior to the first dose of study drug.

- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less
then or equal to 1.

- Subject must have adequate bone marrow, renal and hepatic function per local
laboratory reference range as follows:

- Bone marrow: Absolute Neutrophil Count (ANC) greater then or equal to
1500/microliters; platelets greater then or equal to 150,000/mm^3; hemoglobin
greater then or equal to 9.0 g/dL;

- Renal function: Serum creatinine less then or equal 2.0 mg/dL or calculated
creatinine clearance greater than or equal to 50 mL/min;

- Hepatic function and enzymes: AST and ALT less then or equal to 1.5 x the upper
limit of normal (ULN) of institution's normal range, ALP less then or equal to
2.5 x ULN, and bilirubin less then or equal to 1.0 x ULN. Subjects with bone
metastasis may have ALP less then or equal to 5.0 x ULN.

- Coagulation: aPTT and PT not to exceed less than or equal to 1.2 x ULN.

- Female subjects must be surgically sterile, postmenopausal (for at least one year),
or have negative results for a pregnancy test performed as follows:

- At Screening via a serum sample obtained within 14 days prior to initial study drug
administration, and

- Prior to dosing via a urine sample obtained on Cycle 1 Day 1, if it has been greater
then 7 days since obtaining the serum pregnancy test results.

- Female subjects not surgically sterile or postmenopausal (for at least one year) and
non-vasectomized male subjects must practice at least one of the following methods of
birth control:

- total abstinence from sexual intercourse (minimum one complete menstrual cycle);

- vasectomized partner;

- hormonal contraceptives (oral, parenteral or transdermal) for at least three
months prior to study drug administration;

- Double-barrier method (including condoms, contraceptive sponge, diaphragm or
vaginal ring with spermicidal jellies or cream).

- The subject, or legal representative, must voluntarily sign and date an informed
consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board
(IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria

- The subject has an underlying, predisposing condition of bleeding or currently
exhibits signs of bleeding. The subject has a recent history of thrombocytopenia
associated with bleeding within 1 year prior to first dose of study drug.

- The subject is currently receiving or requires anticoagulation therapy or any drugs
or herbal supplements that affect platelet function, with the exception of low-dose
anticoagulation medications (i.e., Heparin) that are used to maintain the patency of
a central intravenous catheter.

- A female subject is pregnant or breast-feeding.

- The subject has active peptic ulcer disease or other potentially hemorrhagic

- The subject has active immune thrombocytopenic purpura (ITP), autoimmune hemolytic
anemia (AIHA), or a history of being refractory to platelet transfusions (within 1
year prior to the first dose of study drug).

- The subject has received any anti-cancer therapy including chemotherapy,
immunotherapy, radiotherapy, hormonal therapy (with the exception of hormones for
hypothyroidism, estrogen replacement therapy [ERT], anti estrogen analogs, agonists
required to suppress serum testosterone levels [e.g., LHRH, GnRH, etc.] for subjects
with prostate cancer if on a stable dose for at least 21 days prior to the first dose
of study drug), or any investigational therapy with 14 days prior to the first dose
of study drug, or has not recovered to less than a grade 2 clinically significant
adverse effect(s)/toxicity(s) of the previous therapy.

- The subject has received an antibody therapy or other biologic (with the exception of
colony stimulating factors [G-CSF, GM-CSF] or erythropoietin) within 28 days prior to
the first dose of study drug.

- The subject has consumed grapefruit or grapefruit products within 3 days prior to the
first dose of study drug.

- The subject has received steroid therapy for anti-neoplastic intent within 7 days
prior to the first dose of study drug with the exception of inhaled steroids for
asthma, topical steroids, replacement/stress corticosteroids, or corticosteroids
taken as premedication for this study.

- The subject has received aspirin or known CYP3A inhibitor (e.g., ketoconazole) within
7 days prior to the first dose of study drug.

- The subject has undergone an allogeneic stem cell transplant.

- The subject has received radio-immunotherapy within 6 months prior to the first dose
of study drug.

- The subject has a history of hypersensitivity to docetaxel or other polysorbate 80

- The subject has tested positive for human immunodeficiency virus, HIV (due to
potential drug-drug interactions between anti-retroviral medications and navitoclax
(ABT-263), as well as anticipated navitoclax (ABT-263) mechanism based lymphopenia
that may potentially increase the risk of opportunistic infections and potential
drug-drug interactions with certain anti infective agents).

- The subject has a significant history of cardiovascular (e.g., MI, thrombotic or
thromboembolic event in the last 6 months), renal, neurologic, psychiatric,
endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the
investigator would adversely affect his/her participating in this study. Questions
regarding inclusion of individual subjects should be directed to the Abbott Medical
Monitor or designee.

- The subject exhibits evidence of other clinically significant uncontrolled
condition(s) including, but not limited to:

- active systemic fungal infection;

- A diagnosis of fever and neutropenia within 1 week prior to study drug

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Assess the safety profile of navitoclax (ABT-263) when administered in combination with a standard and weekly regimen of docetaxel.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Mack Mabry, MD

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

July 2009

Completion Date:

March 2012

Related Keywords:

  • Solid Tumor



Site Reference ID/Investigator# 51982 Scottsdale, Arizona  85258
Site Reference ID/Investigator# 44182 Fort Lauderdale, Florida  33308
Site Reference ID/Investigator# 43962 Baltimore, Maryland  21231